Open AccessAdoptive immunotherapy for cancer: the next generation of gene‐engineered immune cells
Author(s) -
Berry L. J.,
Moeller M.,
Darcy P. K.
Publication year - 2009
Publication title -
tissue antigens
Language(s) - English
Resource type - Journals
eISSN - 1399-0039
pISSN - 0001-2815
DOI - 10.1111/j.1399-0039.2009.01336.x
Subject(s) - adoptive cell transfer , chimeric antigen receptor , t cell receptor , immunogenicity , immunotherapy , cancer immunotherapy , immune system , biology , cancer research , immunology , effector , antigen , t cell , genetic enhancement , transgene , receptor , gene , genetics
Adoptive cellular immunotherapy involving transfer of tumor‐reactive T cells has shown some notable antitumor responses in a minority of cancer patients. In particular, transfer of tumor‐infiltrating lymphocytes has resulted in long‐term objective responses in patients with advanced melanoma. However, the inability to isolate sufficient numbers of tumor‐specific T cells from most malignancies has restricted the broad utility of this approach. An emerging approach to circumvent this limitation involves the genetic modification of effector cells with T cell receptor (TCR) transgenes or chimeric single‐chain variable fragment (scFv) receptors that can specifically redirect T cells to tumor. There has been much progress in the design of TCR and scFv receptors to enhance the antigen‐specific activation of effector cells and their trafficking and persistence in vivo . Considerable effort has been directed toward improving the safety of this approach and reducing the immunogenicity of the receptor. This review discusses the latest developments in the field of adoptive immunotherapy using genetically modified immune cells that have been transduced with either TCR or scFv receptor transgenes and used in preclinical and clinical settings as anticancer agents.